Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis

Tsu Yi Chao, Yi Ying Wu, Anthony J. Janckila

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The spread of cancer to bone is considered a terminal event. Two main types of bone metastasis can manifest, i.e. osteoblastic and osteolytic. Irrespective of metastatic type, uncoupled bone remodeling is always present and perpetuates a vicious cycle of excess bone resorption and destruction. Biochemical markers of bone metabolism are potentially useful to diagnose metastatic bone disease and to monitor treatment response in cancer patients. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) is a biochemical marker of osteoclast number and activity. Mounting evidence has demonstrated serum TRACP 5b as a useful marker of bone resorption and therefore bears clinical applicability in diagnosis and management of metabolic and pathologic bone diseases. Serum TRACP 5b is among one of the many bone resorption biochemical markers that have been studied to be a surrogate marker of bone metastasis in cancer patients. Its serum level may reflect the degree of lytic bone metastasis and, in turn, the tumor burden within the bone milieu. This review summarizes the development of specific immunoassays for serum TRACP 5b as well as current evidence for its exploitation as a biomarker for diagnosis, treatment response, and prognosis in various cancers with high incidence of bone metastasis including breast, prostate, lung, and multiple myeloma.

Original languageEnglish
Pages (from-to)1553-1564
Number of pages12
JournalClinica Chimica Acta
Volume411
Issue number21-22
DOIs
Publication statusPublished - Nov 2010
Externally publishedYes

Fingerprint

Bone Neoplasms
Acid Phosphatase
Protein Isoforms
Bone
Neoplasm Metastasis
Bone and Bones
Biomarkers
Bone Resorption
Serum
Neoplasms
Bone Remodeling
Metabolic Bone Diseases
Bone Diseases
Osteoclasts
Tumor Burden
Multiple Myeloma
Immunoassay
Tartrate-Resistant Acid Phosphatase
tartaric acid
Prostate

Keywords

  • Bone metastasis
  • Cancer
  • Osteoclast
  • Tartrate-resistant acid phosphatase 5b

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis. / Chao, Tsu Yi; Wu, Yi Ying; Janckila, Anthony J.

In: Clinica Chimica Acta, Vol. 411, No. 21-22, 11.2010, p. 1553-1564.

Research output: Contribution to journalArticle

@article{9404cbfbe9c44f7e9e76d7935bb34d78,
title = "Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis",
abstract = "The spread of cancer to bone is considered a terminal event. Two main types of bone metastasis can manifest, i.e. osteoblastic and osteolytic. Irrespective of metastatic type, uncoupled bone remodeling is always present and perpetuates a vicious cycle of excess bone resorption and destruction. Biochemical markers of bone metabolism are potentially useful to diagnose metastatic bone disease and to monitor treatment response in cancer patients. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) is a biochemical marker of osteoclast number and activity. Mounting evidence has demonstrated serum TRACP 5b as a useful marker of bone resorption and therefore bears clinical applicability in diagnosis and management of metabolic and pathologic bone diseases. Serum TRACP 5b is among one of the many bone resorption biochemical markers that have been studied to be a surrogate marker of bone metastasis in cancer patients. Its serum level may reflect the degree of lytic bone metastasis and, in turn, the tumor burden within the bone milieu. This review summarizes the development of specific immunoassays for serum TRACP 5b as well as current evidence for its exploitation as a biomarker for diagnosis, treatment response, and prognosis in various cancers with high incidence of bone metastasis including breast, prostate, lung, and multiple myeloma.",
keywords = "Bone metastasis, Cancer, Osteoclast, Tartrate-resistant acid phosphatase 5b",
author = "Chao, {Tsu Yi} and Wu, {Yi Ying} and Janckila, {Anthony J.}",
year = "2010",
month = "11",
doi = "10.1016/j.cca.2010.06.027",
language = "English",
volume = "411",
pages = "1553--1564",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "21-22",

}

TY - JOUR

T1 - Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis

AU - Chao, Tsu Yi

AU - Wu, Yi Ying

AU - Janckila, Anthony J.

PY - 2010/11

Y1 - 2010/11

N2 - The spread of cancer to bone is considered a terminal event. Two main types of bone metastasis can manifest, i.e. osteoblastic and osteolytic. Irrespective of metastatic type, uncoupled bone remodeling is always present and perpetuates a vicious cycle of excess bone resorption and destruction. Biochemical markers of bone metabolism are potentially useful to diagnose metastatic bone disease and to monitor treatment response in cancer patients. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) is a biochemical marker of osteoclast number and activity. Mounting evidence has demonstrated serum TRACP 5b as a useful marker of bone resorption and therefore bears clinical applicability in diagnosis and management of metabolic and pathologic bone diseases. Serum TRACP 5b is among one of the many bone resorption biochemical markers that have been studied to be a surrogate marker of bone metastasis in cancer patients. Its serum level may reflect the degree of lytic bone metastasis and, in turn, the tumor burden within the bone milieu. This review summarizes the development of specific immunoassays for serum TRACP 5b as well as current evidence for its exploitation as a biomarker for diagnosis, treatment response, and prognosis in various cancers with high incidence of bone metastasis including breast, prostate, lung, and multiple myeloma.

AB - The spread of cancer to bone is considered a terminal event. Two main types of bone metastasis can manifest, i.e. osteoblastic and osteolytic. Irrespective of metastatic type, uncoupled bone remodeling is always present and perpetuates a vicious cycle of excess bone resorption and destruction. Biochemical markers of bone metabolism are potentially useful to diagnose metastatic bone disease and to monitor treatment response in cancer patients. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) is a biochemical marker of osteoclast number and activity. Mounting evidence has demonstrated serum TRACP 5b as a useful marker of bone resorption and therefore bears clinical applicability in diagnosis and management of metabolic and pathologic bone diseases. Serum TRACP 5b is among one of the many bone resorption biochemical markers that have been studied to be a surrogate marker of bone metastasis in cancer patients. Its serum level may reflect the degree of lytic bone metastasis and, in turn, the tumor burden within the bone milieu. This review summarizes the development of specific immunoassays for serum TRACP 5b as well as current evidence for its exploitation as a biomarker for diagnosis, treatment response, and prognosis in various cancers with high incidence of bone metastasis including breast, prostate, lung, and multiple myeloma.

KW - Bone metastasis

KW - Cancer

KW - Osteoclast

KW - Tartrate-resistant acid phosphatase 5b

UR - http://www.scopus.com/inward/record.url?scp=77956472968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956472968&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2010.06.027

DO - 10.1016/j.cca.2010.06.027

M3 - Article

VL - 411

SP - 1553

EP - 1564

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 21-22

ER -